1-1 of 1
Charlie Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)

Free
Marc Usart, Shivam Rai, Kavi O'Connor, Quentin Kimmerlin, Zachary Zaroogian, Matthew Wereski, Charlie Xu, Craig Masse, Stevan Hubbard, Ross Levine, Maria Kleppe, Radek Skoda, Andrew Dunbar
Journal: Blood
Blood (2025) 146 (Supplement 1): 1983.
https://doi.org/10.1182/blood-2025-1983
Published: 2025